These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3921077)

  • 41. Plasma levels of valproic acid and its metabolites during continued treatment in dogs.
    Löscher W
    J Vet Pharmacol Ther; 1981 Jun; 4(2):111-9. PubMed ID: 6818360
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.
    Sadeque AJ; Fisher MB; Korzekwa KR; Gonzalez FJ; Rettie AE
    J Pharmacol Exp Ther; 1997 Nov; 283(2):698-703. PubMed ID: 9353388
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of medium-chain fatty acid beta-oxidation in vitro by valproic acid and its unsaturated metabolite, 2-n-propyl-4-pentenoic acid.
    Bjorge SM; Baillie TA
    Biochem Biophys Res Commun; 1985 Oct; 132(1):245-52. PubMed ID: 3933498
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes.
    Kassahun K; Hu P; Grillo MP; Davis MR; Jin L; Baillie TA
    Chem Biol Interact; 1994 Mar; 90(3):253-75. PubMed ID: 8168173
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma.
    Bailey MJ; Dickinson RG
    Chem Res Toxicol; 1996; 9(3):659-66. PubMed ID: 8728513
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and gamma-aminobutyric acid (GABA) metabolism in the mouse.
    Nau H; Löscher W
    J Pharmacol Exp Ther; 1982 Mar; 220(3):654-9. PubMed ID: 6801254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Valproic acid has temporal variability in urinary clearance of metabolites.
    Reith DM; Andrews J; McLaughlin D
    Chronobiol Int; 2001 Jan; 18(1):123-9. PubMed ID: 11247111
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effects of carbamazepine on plasma concentrations of valproic acid and its toxic metabolite in epileptic patients].
    Chen ZJ; Wang XD; Zhou LM; Fang ZY; Wang HS; Li JL; Zhou JQ; Huang HB; Huang M
    Yao Xue Xue Bao; 2014 Apr; 49(4):530-4. PubMed ID: 24974473
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Hepatotoxicity of valproic acid treatment].
    Keulen FP; Kochen W
    Klin Padiatr; 1985; 197(5):431-6. PubMed ID: 3934460
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.
    Tong V; Teng XW; Chang TK; Abbott FS
    Toxicol Sci; 2005 Aug; 86(2):427-35. PubMed ID: 15858223
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis.
    Wegner C; Nau H
    Neurology; 1992 Apr; 42(4 Suppl 5):17-24. PubMed ID: 1574172
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Zinc concentrations in mouse embryo and maternal plasma. Effect of valproic acid and nonteratogenic metabolite.
    Wegner C; Drews E; Nau H
    Biol Trace Elem Res; 1990 Jun; 25(3):211-7. PubMed ID: 1698419
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats.
    Blotnik S; Bergman F; Bialer M
    Drug Metab Dispos; 1996 May; 24(5):560-4. PubMed ID: 8723737
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical pharmacokinetics of anticonvulsants.
    Hvidberg EF; Dam M
    Clin Pharmacokinet; 1976; 1(3):161-88. PubMed ID: 797496
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Abnormal metabolism of valproic acid in fatal hepatic failure.
    Kochen W; Schneider A; Ritz A
    Eur J Pediatr; 1983 Oct; 141(1):30-5. PubMed ID: 6416845
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice.
    Löscher W; Nau H
    Neuropharmacology; 1985 May; 24(5):427-35. PubMed ID: 3927183
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Accumulation and washout kinetics of valproic acid and its active metabolites.
    Pollack GM; McHugh WB; Gengo FM; Ermer JC; Shen DD
    J Clin Pharmacol; 1986; 26(8):668-76. PubMed ID: 3098806
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dose-dependent pharmacokinetics of toxic metabolites is not related to increased toxicity following high-dose valproic acid in rats.
    Jung BH; Kim BJ; Lee MS; Lee JH; Oh JH; Lee YJ
    J Appl Toxicol; 2010 Nov; 30(8):775-8. PubMed ID: 21157986
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conjugation of glutathione with a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, catalyzed by rat hepatic glutathione-S-transferases.
    Tang W; Borel AG; Abbott FS
    Drug Metab Dispos; 1996 Apr; 24(4):436-46. PubMed ID: 8801059
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Five doubly unsaturated metabolites of valproic acid in urine and plasma of patients on valproic acid therapy.
    Kochen W; Sprunck HP; Tauscher W; Klemens M
    J Clin Chem Clin Biochem; 1984 Apr; 22(4):309-17. PubMed ID: 6429268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.